News|Articles|December 14, 2018

In the Lab eNewsletter

  • Pharmaceutical Technology\'s In the Lab eNewsletter-01-09-2019
  • Volume 14
  • Issue 1

Histo-Scientific Research Laboratories and Vet Path Services Merge

The merged companies will provide histopathology services in the research and pre-clinical therapeutics markets.

Histo-Scientific Research Laboratories (HSRL), a histology and pathology services provider based in Mount Jackson, VA, announced on Dec. 11, 2018 that it completed its merger with contract histopathology company Vet Path Services (VPS) to provide research and pre-clinical histology, pathology, and archiving services for the biopharmaceutical, medical device, and contract research industries.  

HSRL specializes in histology and pathology services for routine tissue analyses, efficacy determination for new compounds and devices, toxicologic evaluation of products subject to FDA approval, and detailed pathology reporting for good laboratory practices (GLP) studies in the pre-clinical research and development market. VPS offers substantially corresponding histology and pathology expertise that will play a valuable role in growing the combined company’s service capabilities. With the merger, the organization now has footprints in Mount Jackson, VA; Mason, OH; and Worcester, MA.  The company plans to significantly expand its Worcester site, where complex immunohistochemical techniques and image analysis is performed, in order to serve demand for these services in the market. 

“We are very excited to partner with VPS to expand HSRL’s service offerings, and to rapidly scale the combined company to meet the growing demand for high-quality histopathology services in the research and pre-clinical therapeutics markets,” stated Mr. Thomas Galati, founder and CEO of HSRL, who will serve as CEO of the combined entity, in a company press release. “The addition of VPS brings not only valuable technical and operational expertise, but also increased service capabilities and a specialized comprehension of complex histopathology with regard to medical devices.”  

“Our partnership with HSRL represents a highly complementary union of histology and pathology expertise that is unrivaled in the industry,” said founder and vice president of VPS, Chris Johnson, in the release. “The combination creates an organization that has access to over 25 board-certified veterinary pathologists, who together offer a diverse experience base and the scientific ability to accomplish any project.” 

In conjunction with the merger, the new company has received an investment from Ampersand Capital Partners, a leading private equity fund focused on the healthcare sector.

Source: Ampersand Capital Partners


Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.